# Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

> **NCT05239650** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 50 (estimated)

## Conditions studied

- CRC

## Interventions

- **DRUG:** HLX07
- **DRUG:** HLX10
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT05239650
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2025-10-15
- **Final completion:** 2026-10-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239650, "Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05239650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*